Thread by @DrTiffanyL

Dr. Alan Anderson here to present #crizanluzumab (which is approved for age >16 to prevent VOE) and its effect on #priapism. Long prescreening to capture these occ events. Needed 4 in prescreening 14 weeks. 1/n #ASH22

24 patients met the eligibility criteria. Received 5 mg/kg and then q4 weeks and checked outcome at week 26 and treated for 52 weeks. Also reported #PRO. #ASH22 2/n

This is the baseline data -- first reported at age 13-17 years, often daily or every other day. If this is surprising to you, think about how you are asking your #SCD pts about #priapism? It has a significant impact on their life! #ASH22 3/n

Here are the results - the 500fold increase patient on the left had issues with data collection... so they are using median data instead. Hmm. But, at week 12, 25% reduction and at week 15-26 weeks a 72% reduction in events, especially in those with high burden prior! #ASH22 4/n

Final results of SPARTAN trial @NovartisOncMed will come soon - will have to watch out for this. #ASHKudos to Dr. Anderson really acknowledging the pts for sharing this intensely personal experience (and sm/med programs that are getting things done!) #ASH22 5/5

@NovartisOncMed Q&A response: no genotype correlation has been done yet (all but 3 are SS on this small number), more info needed on who have not had less events (but maybe easier to control/less pain/shorter duration), what about those who were on chronic tx? P-selectin biomarker result? #ASH22